A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
This randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized).
The purpose of this study is to compare recurrence-free survival (RFS) between patients with locally advanced renal cell carcinoma randomly assigned to perioperative nivolumab in conjunction with radical or partial nephrectomy with patients randomized to surgery alone.
Participants will not be paid for their participation.
- IRB Number: 1803706029 (EA8143)
- Research Study Identifier: TX8770
- Principal Investigator: Roberto Pili, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required